Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Harvard Apparatus Regenerative Technology ( (HRGN) ) is now available.
On December 30, 2025, Harvard Apparatus Regenerative Technology, Inc. entered into securities purchase agreements with certain investors for a private placement of 411,765 shares of common stock at $1.70 per share, raising approximately $0.7 million. The agreements, which include customary representations, warranties and covenants intended mainly for risk allocation between the parties, underscore a targeted capital-raising move that provides additional funding to the company while emphasizing that these contractual provisions should not be interpreted by stockholders as definitive statements about the company’s current factual condition or future performance.
Spark’s Take on HRGN Stock
According to Spark, TipRanks’ AI Analyst, HRGN is a Underperform.
HRGN faces significant financial challenges, with persistent net losses and cash flow issues. The technical indicators suggest a bearish trend, and the valuation is unattractive with a negative P/E ratio. The lack of positive earnings call updates contributes to a low overall stock score.
To see Spark’s full report on HRGN stock, click here.
More about Harvard Apparatus Regenerative Technology
Harvard Apparatus Regenerative Technology, Inc. operates in the biomedical and regenerative medicine sector, focusing on developing and commercializing technologies related to regenerative therapies and associated medical applications.
Average Trading Volume: 5,109
Technical Sentiment Signal: Sell
Current Market Cap: $33.99M
Learn more about HRGN stock on TipRanks’ Stock Analysis page.